Alnylam Pharmaceuticals, Inc.

Ladies and gentlemen, thank you for standing by and welcome to the Allen Island Pharmaceuticals Q2 2021 earnings call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask a question during the session, you need to press star 1 on your telephone. If you require any further assistance, please press star then 0. I would now like to turn the call over to your host, Christine Lindenboom. You may begin.

Good morning. I'm Christine Lindenboom, Senior Vice President of Investor Relations and Corporate Communications at El Nilem. With me today on the phone are John Merganori, Chief Executive Officer, Tolga Tangular, Chief Commercial Officer, Akshay Vaishnal, President of R&D, Jeff Bolton, Chief Financial Officer, and Yvonne Greenstreet, President and Chief Operating Officer. For those of you participating via conference call, the accompanying slides can be accessed by going to the events section of the investors page of our website, investors.alnyloves.com slash events. During today's call, as outlined in slide two, John will provide some introductory remarks and provide general context. Tolga will provide an update on our global commercial progress. Akshay will review recent clinical and preclinical updates. Jeff will review our financials, and Yvonne will provide a brief summary of upcoming milestones before opening the call to your questions. I would like to remind you that this call will contain remarks concerning Alnyloves' future expectations plans and prospects, which constitute forward-looking statements for the purposes of the safe harbor provision under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those discussed in our most recent quarterly report on file with the SEC. In addition, any forward-looking statements represent our views only as of the date of this recording and should not be relied upon as representing our views as of any subsequent date. We specifically disclaim any obligations to update such statements. With that, I'd like to turn the call over to John. John?

Thanks, Christine, and thank you, everyone, for joining the call today. In the second quarter and recent period, we made tremendous progress bringing RNAi therapeutics to patients around the world with our commercial, medical, and R&D efforts, while delivering solid financial performance. To start, Our teams delivered steady, ongoing commercial execution and continued revenue growth, including 12% quarterly growth for Ampatro, strengthening of Givlari performance, and a continued impressive uptake for Oxalumo. On our pipeline efforts, highlights include excellent progress building our ATTR Ameliodosis franchise. We completed enrollment in the Apollo B Phase 3 study of Petit Sarand. and expect to complete enrollment in the Helios B phase three study of Lutrisiran within the next two weeks. Significantly ahead of schedule and already with more than 600 patients enrolled. We also submitted our Lutrisiran NDA based on the Helios A results in patients with HATTR amyloidosis with polyneuropathy and the FDA accepted our submission assigning a BDUFA date in April of 2022. Furthermore, We initiated a biannual dosing study of butresaran, and we introduced a new preclinical program, ALN-TTR-SC04, which we believe could enable an annual dosing regimen. We also advanced programs in our earlier stage clinical pipeline, including new positive interim data from the Phase I study of Zabiseran, our investigational RNAi therapeutic for hypertension, which is now advanced into the CARDIA Phase II program. We believe all of these achievements represent meaningful progress toward our Alnylam P to the fifth by 25 goals. A bold vision for Alnylam with transformative medicines in both rare and common diseases for patients around the world. And a robust and high yielding pipeline of first and or best in class product candidates from our organic product engine. All this while delivering exceptional financial performance. So with that, let me now turn the call over to Tolga for a review of our commercial results. Tolga.